Lincoln Pharmaceuticals (BOM:531633) Cyclically Adjusted Revenue per Share: ₹295.59 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531633 Lincoln Pharmaceuticals Ltd BOM:531633
81 GF Score
Price ₹622.35
GF Value ₹710.25
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share?

Lincoln Pharmaceuticals BOM:531633 +1.82% 81 Cyclically Adjusted Revenue per Share is ₹295.59 as of Jun. 2026. GuruFocus rates BOM:531633 with a GF Score™ of 81/100 and a GF Value™ of ₹710.25 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lincoln Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹88.508. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹295.59 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Lincoln Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 2.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lincoln Pharmaceuticals was 6.80% per year. The lowest was 4.70% per year. And the median was 6.40% per year.

As of today (2026-08-21), Lincoln Pharmaceuticals's current stock price is ₹622.35. Lincoln Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹295.59. Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 2.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lincoln Pharmaceuticals was 3.29. The lowest was 0.96. And the median was 1.71.


Lincoln Pharmaceuticals  (BOM:531633) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=622.35/295.59
=2.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lincoln Pharmaceuticals was 3.29. The lowest was 0.96. And the median was 1.71.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Lincoln Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Lincoln Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 234.57 252.68 270.26 282.70 289.94

Lincoln Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 287.16 290.55 290.31 289.94 295.59

BOM:531633 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lincoln Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lincoln Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


BOM:531633
81GF Score
Lincoln Pharmaceuticals Ltd BOM:531633
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lincoln Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lincoln Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=88.508/167.3573*167.3573
=88.508

Current CPI (Jun. 2026) = 167.3573.

Lincoln Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 45.557 105.961 71.954
201612 35.137 105.196 55.900
201703 59.504 105.196 94.665
201706 74.924 107.109 117.069
201709 44.814 109.021 68.793
201712 40.102 109.404 61.345
201803 30.831 109.786 46.998
201806 49.886 111.317 75.000
201809 51.302 115.142 74.567
201812 42.186 115.142 61.317
201903 34.990 118.202 49.541
201906 48.370 120.880 66.968
201909 56.361 123.175 76.577
201912 49.304 126.235 65.365
202003 34.396 124.705 46.160
202006 51.905 127.000 68.399
202009 63.057 130.118 81.104
202012 57.282 130.889 73.242
202103 35.014 131.771 44.470
202106 61.015 134.084 76.156
202109 63.661 135.847 78.427
202112 59.865 138.161 72.516
202203 49.269 138.822 59.396
202206 61.606 142.347 72.430
202209 70.208 144.661 81.223
202212 66.783 145.763 76.677
202303 53.494 146.865 60.958
202306 67.691 150.280 75.383
202309 77.897 151.492 86.055
202312 73.119 152.924 80.020
202403 66.474 153.035 72.695
202406 73.542 155.789 79.003
202409 80.514 157.882 85.346
202412 73.173 158.323 77.348
202503 83.982 157.552 89.209
202506 76.937 159.755 80.598
202509 81.584 162.289 84.132
202512 83.045 163.281 85.118
202603 93.522 164.272 95.278
202606 88.508 167.357 88.508

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹295.59 mean?
Lincoln Pharmaceuticals (BOM:531633) has a Cyclically Adjusted Revenue per Share of ₹295.59 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lincoln Pharmaceuticals and its competitors.
Is Lincoln Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Lincoln Pharmaceuticals' current Cyclically Adjusted Revenue per Share is ₹295.59. Overall, Lincoln Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS?
Lincoln Pharmaceuticals' Cyclically Adjusted Revenue per Share of ₹295.59 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lincoln Pharmaceuticals and its competitors. Lincoln Pharmaceuticals's current Cyclically Adjusted Revenue per Share is ₹295.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (BOM:531633) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹710.25, compared to a current price of ₹622.35 — trading 12.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹295.59. Lincoln Pharmaceuticals' overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Lincoln Pharmaceuticals (BOM:531633), the current Cyclically Adjusted Revenue per Share is ₹295.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lincoln Pharmaceuticals (BOM:531633) Overvalued in 2026?

Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued. The current stock price of ₹622.35 is trading 12.4% below its estimated GF Value™ of ₹710.25. GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for BOM:531633:

  • Cyclically Adjusted Revenue per Share: ₹295.59
  • GF Value™: ₹710.25 vs. price of ₹622.35 (12.4% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the BOM:531633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lincoln Pharmaceuticals Business Description

Other Exchanges LINCOLN:India
Address Science City Road, Lincoln House, Behind Satyam Complex, Sola, Ahmedabad, GJ, IND, 380060
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
81GF Score

Get the complete analysis for BOM:531633

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹622.35
Price
₹710.25
GF Value